Related Experiment Video
Updated: Jul 7, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges
M H Baumann1, R D Clark, F H Franken
1Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Suite 4500, Baltimore, MD 21224, USA. mbaumann@mail.nih.gov
Abstract:
3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) stimulates the transporter-mediated release of monoamines, including 5-HT. High-dose exposure to MDMA causes persistent 5-HT deficits (e.g. depletion of brain 5-HT) in animals, yet the functional and clinical relevance of such deficits are poorly defined. Here we examine functional consequences of MDMA-induced 5-HT depletions in rats. Male rats received binges of three i.p. injections of MDMA or saline, one injection every 2 h; MDMA was given at a threshold pharmacological dose (1.5 mg/kgx3, low dose) or at a fivefold higher amount (7.5 mg/kgx3, high dose). One week later, jugular catheters and intracerebral guide cannulae were implanted. Two weeks after binges, rats received acute i.v. challenge injections of 1 and 3 mg/kg MDMA. Neuroendocrine effects evoked by i.v. MDMA (prolactin and corticosterone secretion) were assessed via serial blood sampling, while neurochemical effects (5-HT and dopamine release) were assessed via microdialysis in brain. MDMA binges elevated core temperatures only in the high-dose group, with these same rats exhibiting approximately 50% loss of forebrain 5-HT 2 weeks later. Prior exposure to MDMA did not alter baseline plasma hormones or dialysate monoamines, and effects of i.v. MDMA were similar in saline and low-dose groups. By contrast, rats pretreated with high-dose MDMA displayed significant reductions in evoked hormone secretion and 5-HT release when challenged with i.v. MDMA. As tolerance developed only in rats exposed to high-dose binges, hyperthermia and 5-HT depletion are implicated in this phenomenon. Our results suggest that MDMA tolerance in humans may reflect 5-HT deficits which could contribute to further dose escalation.
Insights
High-dose 3,4-Methylenedioxymethamphetamine (MDMA) causes persistent serotonin (5-HT) deficits in rats, leading to reduced neuroendocrine and neurochemical responses to subsequent MDMA challenges. This suggests 5-HT depletion may drive MDMA tolerance and dose escalation in humans.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is known to affect monoamine release, particularly serotonin (5-HT).
- High-dose MDMA exposure in animals can lead to persistent deficits in brain 5-HT, but their functional significance remains unclear.
Purpose of the Study:
- To investigate the functional consequences of MDMA-induced 5-HT depletions.
- To examine the impact of prior MDMA exposure on neuroendocrine and neurochemical responses to acute MDMA challenges in rats.
Main Methods:
- Rats received high-dose (7.5 mg/kgx3) or low-dose (1.5 mg/kgx3) MDMA or saline binge injections.
- Two weeks post-binge, rats were challenged with intravenous MDMA (1 and 3 mg/kg).
- Neuroendocrine responses (prolactin, corticosterone) and neurochemical changes (5-HT, dopamine) were measured.
Main Results:
- High-dose MDMA induced hyperthermia and approximately 50% forebrain 5-HT depletion two weeks later.
- Rats pretreated with high-dose MDMA showed reduced hormone secretion and 5-HT release upon MDMA challenge.
- Tolerance to MDMA's effects developed only in the high-dose group, implicating hyperthermia and 5-HT depletion.
Conclusions:
- MDMA-induced 5-HT depletion is functionally relevant, impairing neuroendocrine and neurochemical responses.
- Serotonin deficits may contribute to the development of MDMA tolerance.
- These findings suggest a potential mechanism for MDMA dose escalation in humans due to 5-HT deficits.

